CLINICAL AND MICROBIOLOGICAL RATIONALE FOR COMBINATION THERAPY FOR NONGONOCOCCAL INFLAMMATORY DISEASES OF THE UROGENITAL TRACT IN REPRODUCTIVE-AGED WOMEN


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To study the clinical and microbiological efficiencies and validity of a comprehensive approach to safocid and hexicon therapy for nongonococcal inflammatory diseases of the female urogenital tract. Material and methods. Real-time polymerase chain reaction, cervical canal discharge microscopy, and microbiocenosis examination were made. The combined drug safocid and the antiseptic hexicon were used in accordance with the manufacturer’s recommendations. Results. Varying combinations of obligate and opportunistic bacteria were found in patients with inflammatory diseases of the urogenital tract. According to the treatment option, the patients were divided into two groups: Group 1 (a basis group) was treated with etiotropic agents; Group 2 used the combined drug safocid and hexicon vaginal suppositories. A comparison group consisted of 30 apparently healthy women. The maximum etiological and microbiological efficiencies were revealed in the combination therapy group. Conclusion. The use of a combination of the combined drug safocid and the antiseptic hexicon for the treatment of inflammatory diseases of the urogenital tract contributes to the normalization of the resident microflora, prevents vaginal colonization with yeast-like fungi, and produces a high etiological cure rate.

Full Text

Restricted Access

About the authors

O. I LETYAEVA

South Ural State Medical University, Ministry of Health of Russia

Email: olga-letyaeva@yandex.ru
Chelyabinsk

I. I DOLGUSHIN

South Ural State Medical University, Ministry of Health of Russia

Chelyabinsk

References

  1. Кира Е.Ф. Комбинированная терапия инфекционных заболеваний женских половых органов. Гинекология. 2010; 12(1): 26-9.
  2. Кубанова А.А., Рахматулина М.Р. Урогенитальные инфекционные заболевания, вызванные генитальными микоплазмами. Клинические рекомендации. Вестник дерматологии и венерологии. 2009; 3: 78-82.
  3. Летяева О.И., Гизингер О.А., Зиганшин О.Р. Современные возможности терапии воспалительных заболеваний урогенитального тракта негонококковой этиологии у женщин. Клиническая дерматология и венерология. 2011; 4: 95-100.
  4. Фофанова И.Ю. Роль генитальной условно-патогенной микрофлоры в акушерстве и гинекологии. Г инекология. 2008; 10(2): 52-8.
  5. Bradshaw C.S., Tabrizi S.N., Fairley C.K., Morton A.N., Rudland E., Garland S.M. The association of Atopobium vaginae and Gardnerella vaginalis with bacterial vaginosis and recurrence after oral metronidazole therapy. J. Infect. Dis. 2006; 194(6): 828-36.
  6. Donders G., Bellen G., Rezeberga D. Aerobic vaginitis in pregnancy. Br. J. Obstet. Gynaecol. 2011; 118(10): 1163-70.
  7. Прилепская В.Н., Байрамова Г.Р. Вагинальная микоэкосистема влагалища в норме и при патологии. Гинекология. 2009; 11(3): 9-11.
  8. Хрянин А.А., Решетников О.В. Использование макролидов в акушерстве в соответствии с принципами доказательной медицины (рациональной фармакотерапии). Гинекология. 2010; 12(5): 4-9.
  9. Кисина В.И. Клинические аспекты и лечение урогенитального трихомониаза препаратами группы 5-нитромидазолов. Consilium medicum. 2003; 5(3): 162-4.
  10. Рахматуллина М.Р., Шаталова А.Ю. Новые возможности терапии ассоциированных урогенитальных заболеваний. В кн.: Тезисы XI Всероссийского съезда дерматовенерологов и косметологов. Екатеринбург; 2010: 86-7.
  11. Ferris M.J., Masztal A., Aldridge K.E., Fortenberry J.D., Fidel P.L.Jr, Martin D.H. Association of Atopobium vaginae, a recently described metronidazole resistant anaerobe, with bacterial vaginosis. BMC Infect. Dis. 2004; 4(1): 5-13.
  12. Ling Z., Kong J., Liu F., Zhu H., Chen X., Wang Y. et al. Molecular analysis of the diversity of vaginal microbiota associated with bacterial vaginosis. BMC Genomics. 2010; 11: 488.
  13. De Backer E., Verhelst R., Verstraelen H., Claeys G., Verschraegen G., Temmerman M., Vaneechoutte M. Antibiotic susceptibility of Atopobium vaginae. BMC Infect. Dis. 2006; 6(1): 51.
  14. Donders G.G., Van Calsteren K., Bellen G., Reybrouck R., Van den Bosch T., Riphagen I., Van Lierde S. Predictive value for preterm birth of abnormal vaginal flora, bacterial vaginosis and aerobic vaginitis during the first trimester of pregnancy. Br. J. Obstet. Gynaecol. 2009; 116(10): 1315-24.
  15. Ferris M.J., Norori N., Zozaya-Hinchliffe M., Martin D.H. Cultivation-independent analysis of changes in bacterial vaginosis flora following metronidazole treatment. J. Clin. Microbiol. 2007; 45(3): 1016-8.
  16. Кисина В.И. Оптимизация подходов к лечению кандидоза вульвы и влагалища. Клиническая дерматология и венерология. 2010; 2: 96-103.
  17. Tempera G., Furneri P.M. Management of aerobic vaginitis. Gynecol. Obstet. Invest. 2010; 70(4): 244-9.
  18. Yamamoto T., Zhou X., Williams C.J., Hochwalt A., Forney L.J. Bacterial populations in the vaginas of healthy adolescent women. J. Pediatr. Adolesc. Gynecol. 2009; 22(1): 11-8.
  19. Theron M.M., Janse Van Rensburg M.N., Chalkley L.J. Nitroimidazole resistance genes (nimB) in anaerobic Gram-positive cocci (previously Peptotreptococcus spp.). J. Antimicrob. Chemother. 2004; 54(1): 240-2.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media